New registry to track COVID-19 drug safety in pregnancy
NCT ID NCT05013632
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 34 times
Summary
This study enrolls 2,000 pregnant women who had mild to severe COVID-19 and were treated with antiviral drugs or monoclonal antibodies. Researchers will compare their pregnancy outcomes and their babies' health up to 12 months old against those who did not receive these treatments. The goal is to better understand the safety of these medications during pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pregistry
RECRUITINGLos Angeles, California, 90045, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.